H.C. Wainwright & Co., LLC

Join Sam Tabar, Chief Executive Officer of Bit Digital | NASDAQ: BTBT, for an engaging conversation with HCW Research Analyst Kevin Dede on Wednesday, February 12, at 2:30 PM EST. Together, they will delve into the evolution of Bit Digital, a company that started with bitcoin mining and is now at the forefront of data center infrastructure. The discussion will cover the company’s expanding business model, including high-performance computing (HPC) services and hosting, while also highlighting its continued focus on bitcoin mining and the strategic conversion of Ethereum yield into additional bitcoin.   To register, visit https://ct.to/MpmvKiI

On Friday, February 7 at 3pm EST, join HCW’s Andres Maldonado and Andrew Fein for an in-depth virtual KOL call featuring Dr. Edwin A. Alvarez, Professor in the Department of Gynecologic Oncology and Gynecologic Oncology Clinical Trials Director at the University of California, San Francisco. Together, they will explore the rapidly evolving landscape of Gynecologic Oncology, focusing on the advancements in novel antibody-drug conjugate (ADC) therapies for cervical cancer, ovarian cancer, and other indications. The discussion will also cover key upcoming data releases at ASCO GU as well as throughout 2025, and conclude with a live Q&A. To join, register at https://ct.to/DZrMk4p

Join us this Thursday, February 6 at 11am EST for an exclusive KOL panel discussion, moderated by HCW Research Analyst Arthur He, featuring Dr. Kathryn Wagner, Professor Emerita of Neurology and Neuroscience at Johns Hopkins School of Medicine, and Dr. Nivedita Jerath, Neuromuscular Director at AdventHealth Neuroscience Institute. Together, they will explore the evolving landscape of care for Duchenne Muscular Dystrophy (DMD), focusing on the transformative potential of gene therapy and diving into the latest advancements, opportunities, and challenges in efforts to enhance the lives of DMD patients. Secure your spot at https://lnkd.in/gfFEFuEw

We are pleased to have served as the Exclusive Placement Agent for Elicio Therapeutics’ $10 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

Arqit Chief Executive Officer, Andy Leaver, and Chief Financial Officer, Nick Pointon, will be joining HCW Research Analyst Scott Buck in our upcoming HCW@Home on February 6 at 10am EST. The virtual fireside chat will cover a range of topics, including the threat quantum computing poses to data security, Arqit’s current product suite, strategies to address the quantum threat, as well as the company’s revenue opportunities, sales pipeline, profitability outlook, and balance sheet positioning. Register at https://lnkd.in/e_FKwmN6

We are pleased to have served as Co-Manager for Disc Medicine’s $225.5 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

Dr. Manish Sagar, Professor of Medicine, Virology, Immunology, and Microbiology at Boston University School of Medicine, will be featured in our Biotech Breakthroughs series this Friday, January 31 at 10am EST. Moderated by HCW Research Analyst Patrick Trucchio, the discussion will explore various treatment approaches for the novel human immunodeficiency virus (HIV), with Dr. Sagar sharing his expertise in HIV-1 transmission and the associated biological mechanisms. Biotech Breakthroughs is a monthly discovery series featuring key opinion leaders, focusing on novel technologies, modalities, and delivery mechanisms, typically aligned with key value-generating data readouts that have the potential to enable new treatments across multiple disease areas. Register for the series and stay updated here: https://lnkd.in/e7x8Pev6

For 11 consecutive years, H.C. Wainwright & Co. has maintained our position as #1 Investment Bank for confidentially marketed public offerings, registered directs, private placements, and ATM offerings in PlacementTracker’s Market League Tables. Since the start of 2024, we executed over 345 transactions totaling over $15 billion in transaction value. The HCW team has been ranked #1 underwriter/ placement agent by deal volume cumulatively since 1998. We are honored to maintain this top position and continue to serve public and private companies across multiple sectors and regions, providing corporate finance, strategic advisory and related services. View all of our transactions online at www.hcwco.com/transactions. Source: PlacementTracker

Join us on Tuesday, January 28 at 11am EST for an HCW@Home virtual fireside chat, featuring a panel of experts from Gyre Therapeutics. Chief Executive Officer Han Ying, Regulatory Affairs Consultant Suzana Corritori, and Clinical Development Consultant Que (Roger) Liu will be joined by HCW Research Analyst Ed Arce for an in-depth discussion on Gyre’s lead drug, F351. They will cover the latest advancements, the drug's key indications, and the company’s strategic outlook. Please visit https://lnkd.in/e2QiCud8 to register.

Next Tuesday, BTCS Inc. (Nasdaq: BTCS) will be participating in our HCW@Home Series. The virtual fireside chat will be hosted by covering Research Analyst Kevin Dede and feature BTCS Chief Executive Officer Charles Allen; Vice President of Engineering Ben Hunter; and former Ethereum Ecosystem Lead and current Blockdaemon consultant Freddy Zwanzger. The discussion will highlight the recent innovations to blockchain technology, insights into the rapidly evolving Ethereum ecosystem, and BTCS’ role as a participant in Ethereum’s infrastructure.   To join, please register at https://lnkd.in/gmnTXHW6